anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cerebellum is an important brain structure for the future development of motor, cognitive, and behavioral abilities in children. This structure undergoes its most significant growth during the third trimester of pregnancy. Prematurity gathers several risk factors for cerebellar impairment and underdevelopment, and among them is ventricular dilatation following germinal matrix intraventricular hemorrhage (GMH-IVH). In this report, we illustrate how this prevalent complication associated with prematurity may induce secondary cerebellar cortical damage. A premature male born by an emergency Caesarean section displayed massive GMH-IVH at brain ultrasound performed after three hours of extrauterine life and died after 18 hours of life, despite maximized vital support. We report a postmortem histopathological specimen of the cerebellar cortex showing the disruption of the external granular layer (EGL) by hemorrhagic content flowing from the supratentorial ventricles into the fourth ventricle and cisterna magna. The expansion of the ventricular system and the presence of blood in the lateral ventricles can cause inflammation and damage to the cerebellar gyri. Experimental models have shown a thinning of the EGL, suggesting that blood surrounding the cerebellum has a harmful action. Additionally, a sudden influx of cerebrospinal fluid from the lateral ventricles may directly contribute to cerebellar damage, indicating that this may be another way in which the cerebellar gyri are impaired during acute severe GMH-IVH. This is the first histopathologically confirmed case of acute disruption in the cerebellar cortex during a GMH-IVH in a premature baby.
BACKGROUND: Influenza vaccination is recommended for Australians 18+ years old with medical risk factors, but coverage is suboptimal. We aimed to examine whether automatic, opportunistic patient reminders (SMS and/or printed) before appointments with a general practitioner increased influenza vaccination uptake.
METHODS: This clustered non-randomised feasibility study in Australian general practice included patients aged 18-64 years with at least one medical risk factor attending participating practices between May and September 2021. Software installed at intervention practices identified unvaccinated eligible patients when they booked an appointment, sent vaccination reminders (SMS on booking and 1 h before appointments), and printed automatic reminders on arrival. Control practices provided usual care. Clustered analyses adjusted for sociodemographic differences among practices were performed using logistic regression.
RESULTS: A total of 12,786 at-risk adults attended 16 intervention practices (received reminders = 4066; 'internal control' receiving usual care = 8720), and 5082 individuals attended eight control practices. Baseline influenza vaccination uptake (2020) was similar in intervention and control practices (∼34%). After the intervention, uptake was similar in all groups (control practices = 29.3%; internal control = 30.0%; intervention = 31.6% (p-value = 0.203). However, SMS 1 h before appointments increased vaccination coverage (39.3%, adjusted OR = 1.65; 95%CI 1.20;2.27; number necessary to treat = 13), especially when combined with other reminder forms. That effect was more evident among adults with chronic respiratory, rheumatologic, or inflammatory bowel disease.
CONCLUSION: These findings indicate that automated SMS reminders delivered at proximate times to appointments are a low-cost strategy to increase influenza vaccination among adults at higher risk of severe disease attending Australian general practices.
BACKGROUND: Sex is a determinant of the incidence and etiology of arrhythmia. Observational and basic studies suggest that sex hormones are essential in this process; however, the relationship between sex hormones and arrhythmia remains unclear. Mendelian randomization (MR) was used to investigate the causal relationships between sex hormone levels, arrhythmia, and electrocardiographic (ECG) indices.
METHODS: Large genome-wide association studies (GWAS) data on sex hormones, stratified by sex, from the UK biobank consortium, were used as exposure data, and data on atrial fibrillation (AF), atrioventricular block, sick sinus syndrome, paroxysmal tachycardia, and ECG indices were obtained from the FinnGen consortium and summarized large GWAS data. Inverse variance weighting or wald odds was used as the primary analytical method, and weighted medians and MR-Egger regression were used for complementary analyses. The results of the MR of sex hormones and AF from different sources were analyzed using a meta-analysis. Summary-data-based MR analysis was utilized to explore the relationship between sex-hormone related drugs and arrhythmia.
RESULTS: In men, genetically predicted higher estradiol concentrations were associated with a lower risk of AF (odds ratio: 0.908 [0.852-0.967]; p = 0.0029], whereas genetically predicted higher concentrations of total testosterone were associated with lower heart rate variability. Sex hormones showed no association with atrioventricular block, sick sinus syndrome, paroxysmal tachycardia, resting heart rate, P wave duration, P wave terminal force in lead V1 [PTFV1], PR interval, QRS duration, QTc [QT interval corrected by heart rate], ST duration, spatial [spQRSTa] and frontal [fQRSTa] QRS-T angles in males. In females, there was no significant evidence that sex hormones are associated with arrhythmias or ECG indices.
CONCLUSION: In this study, we identified a potential causal relationship between estradiol and the risk of AF in males. However, there was no significant association between sex hormones and either arrhythmias or ECG indices in females. These results suggested that sex hormones may play a limited role in cardiac arrhythmias, which requires further verification.
Disclosed is a method for preparing a natural antioxidant which shows superior antioxidant activity and can increase the productivity of the antioxidant by using leaves, stems and roots of Lespedeza bicolor turczaninow var., and all of leaves, above-ground parts, and roots of Plantago asiatica. To this end, the method comprises: a sorting step in which Lespedeza bicolor turczaninow var. and Plantago asiatica are dried, cut and sorted according to parts; a pulverizing step in which each part of the Lespedeza bicolor turczaninow var. and Plantago asiatica is pulverized; an ultrasonic extraction step in which the leaves of Lespedeza bicolor turczaninow var. are mixed with 100% fermented alcohol, and the stems and roots of Lespedeza bicolor turczaninow var. are mixed with 50% fermented alcohol, and then ultrasonic extraction is performed to produce a leaf extract, a stem extract, and a first root extract, whereas the flowers and roots of Plantago asiatica are mixed with 70% fermented alcohol, and the above-ground part of Plantago asiatica is mixed with 100% fermented alcohol, and ultrasonic extraction is performed to produce a leaf extract, an above-ground part extract, and a second root extract, and the extracts are mixed together to produce a mixture; and a condensation step in which the mixture is filtered under reduced pressure and then condensed. The antioxidant produced according to the present invention has superior extraction yield and improved antioxidant action.
FIELD: medicine, pharmacology. SUBSTANCE: the suggested method of applying agonists or antagonists of P 2 - purinoceptors deals with modulating glutamate-induced physiological functions due to application of pharmacological composition of mentioned new properties. Moreover, agonists of P 2 -purinoceptors are represented by 5-adenilylimidodiphosphate, and antagonists - by basilene blue and cibacron blue 3GA reagents. Inclusion of purinoceptors into the process of glutamate-dependent neurotoxicity development is detected for the first time. EFFECT: increased number of preparations of mentioned indication. 11 cl, 10 dwg
PURPOSE:To provide an anti-suntan cosmetic having excellent adhesivity, spreadability, slipperiness, covering power and ultraviolet shielding capacity and high safety, by compounding fine powder of a flat granular resin essentially uniformly containing an ultraviolet absorber. CONSTITUTION:100pts.wt. of a resin (preferably polyethylene, nylon, polymethyl methacrylate, etc.) is essentially uniformly incorporated with 1-50pts.wt. of an ultraviolet absorber. Flat granular fine power of the obtained resin satisfying the formulas l>m>n and l/n>=2 (l, m and n are major diameter, minor diameter and thickness of the granule, respectively) is compounded to an anti-suntan cosmetic preferably at an amount of 2-50pts.wt. of the power per 100pts.wt. of the cosmetic. Extremely high ultraviolet-shielding effect can be attained by the addition of a small amount of the absorber and the anti-suntan cosmetic produced by this process has excellent spreadability on the skin, makeup effect, adhesivity, water-resistance, durability and removability compared with conventional cosmetic.
<P>PROBLEM TO BE SOLVED: To allow a medical doctor to intuitively grasp the consultation history of a patient.  <P>SOLUTION: A history information storage part 182 stores history information including a patient ID; a clinical department of the patient; and clinical date specifying information which indicates a clinical date in the clinical department of the patient in a prescribed period, which is specified by the patient ID. A display color storage part 1831 stores the display color of each clinical department and the display color of non-clinical date. When a consultation history display request including the patient ID is transmitted from a terminal apparatus, a consultation history display data generating means 15 generates consultation history display data for displaying a consultation history display graph, based on the history information of the applicable patient stored in the history information storage part 182 and the content of the display color storage part 1831. The consultation history display graph is a band graph for the portion of the prescribed period with one day as a unit length, where an area corresponding to the clinical date is made to be the display color corresponding to the department of a clinical examination performed on the day.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The utility model relates to a dual purpose pillow for the neck portion and the waist portion, which comprises a pillow core, a pillow slip, and further a hard pillow seat. The body of the hard pillow seat is a hard strip shaped rectangular body. In use, the pillow core is put into the main slip of the pillow slip, and the pillow slip is wound around the hard pillow seat into a cylindrical pillow body, then the cylindrical pillow body is fixed by fixing pieces. The shape of the pillow slip is rectangular, and besides the main slip, a first laying slip is included on one end along the length direction thereof for laying the hard pillow seat, and a second laying slip is further included on one end along the width direction of the pillow slip for laying the hard pillow seat. And the pillow can be used for the waist in use. Because of the supporting function of the hard pillow seat, the utility model can ensure that the pillow body will not deform in the use process, thus has function of supporting the neck; the utility model can also be used to support the waist by changing the laying position of the hard pillow seat in use.
Disclosed is an antiviral agent-supporting sheet which is capable of maintaining antiviral activity such as anti-influenza virus activity for a long time.
The antiviral agent-supporting sheet is obtained by adhering an antiviral agent such as an anti-influenza virus agent in the form of fine particles, which produce hydroxyl radicals, to a sheet-like material by means of an adhesive. As the antiviral agent in the form of fine particles, fine particles obtained by pulverizing a hydrate of fired dolomite are used. The adhesive contains a polyvinyl alcohol that has a polymerization degree of 250-1,000. The polyvinyl alcohol preferably has a saponification degree of 35-99% by mole. The adhesive may additionally contain a polyolefin resin in the form of fine particles having a number average particle diameter of 1 μm or less. As the sheet-like material, a nonwoven fabric, a knitted or woven fabric, a paper sheet or the like is used.
PURPOSE: A dual-functional liposome containing a composite of a transition metal element and a negative charge chemical drug is provided to enhance resolution and accuracy of an image for cancer diagnosis. CONSTITUTION: A dual-functional liposome for diagnosis and treatment contains a composite containing a transition metal and a negative charge chemical drug. The transition metal is La, Pr, Nd, Gd, or Tb. The chemical is an anticancer chemical drug. The liposome is a nanoliposome and contains a stealth agent conjugated on the surface thereof. A method for preparing the liposome comprises: a step of forming a lipid thin film using lipid; a step of hydrating the lipid thin film with a hydration solution; a step of encapsulating the transition metal in the liposome and collecting a liposome solution; and a step of contacting the liposome solution with the negative charge chemical drug.
This invention includes: (1) a training database establishing step; (2) a first initial solution generating step; (3) a 2nd to Mth solutions generating step; (4) three objective functions generating step; (5) a best solution optimization step; and (6) a finishing step. Based on the neck circumference (NC), waist circumference (WC), and average blood pressure after waking up (AM), the multiple personal training data can be distributed and then be divided into N groups. In each group, one fuzzy rule is composed by a NC fuzzy membership function, a WC fuzzy membership function, an AM fuzzy membership 
function, and a sleep apnea-hypopnea index (AHI) output that is generated randomly. According, all N fuzzy rules can be obtained. The 2nd to Mth solutions can be generated by adding randomly values from the first solution accordingly. By using the existing genetic algorithm technique, a best solution can be found by repeated calculations. This invention can be applied on the person who takes sleeping pills, hypotensive drugs, or smokes. No expensive device nor complicated operation is needed. In addition, it is flexible to select the person with specific conditions.
PURPOSE OF REVIEW: Transgender and gender-diverse individuals (TGD) are at risk for sexually transmitted infections. Gender affirmation surgery is a cornerstone of care for many TGD individuals. For genital gender affirmation, the surgical creation of a vagina may be performed through a number of techniques. Those who have undergone vaginoplasty have unique anatomical and biopsychosocial considerations, which we discuss.
RECENT FINDINGS: While sexually-transmitted infections including HPV, HSV, HIV, gonorrhea, and chlamydia, have been described in TGD individuals after vaginoplasty, the reports are very rare, and the provider should maintain an index of suspicion and maintain a broad differential for symptoms including neovaginal discharge. We discuss the association of the neovaginal microbiota composition with bacterial vaginosis, and how its modulation could potentially reduce bacterial vaginosis and sexually transmitted infection risk.
SUMMARY: We examine the literature regarding sexually-transmitted infections following vaginoplasty, and the neovaginal microbiome and its similarities and differences relative to the natal vaginal microbiome.
Minimal sedation (and early extubation if possible). Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of \>85mmHg.
Stroke is a serious and life threatening disease. About 85% of all strokes are ischemic, caused by a blood clot or plaque that blocks a blood vessel in the brain. The thrombolytic drug tissue plasminogen activator (tPA) is the only early treatment for acute ischemic stroke approved by the FDA. Treatment with tPA must be administered within three hours of the stroke onset. Furthermore, tPA treatment carries a recognized risk of bleeding in the brain. GM602 is an investigational drug that may act as a neuroprotectant in patients who have had a stroke. It is thought to stop cell death and reduce inflammation in the injured area of the brain. This study is designed to evaluate the safety and efficacy of GM602 administered intravenously to patients in three consecutive daily doses of 320 mg/dose or 480 mg/dose, the initial dose administered within 18 hours after onset of acute ischemic stroke in the Middle Cerebral artery region.
Patients and their families and caregivers should be advised that Savella is a selective norepinephrine and serotonin reuptake inhibitor and therefore belongs to the same class of drugs as antidepressants. Patients, their families and their caregivers should be advised that patients with depression may be at increased risk for clinical worsening and/or suicidal ideation if they stop taking anti-depressant medication, change the dose, or start a new medication.

Patients, their families and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania or other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during treatment with Savella or other drugs that inhibit the reuptake of norepinephrine and/or serotonin, and when the dose is adjusted up or down. Families and caregivers of patients should be advised to observe for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. [see Box Warning and Warnings and Precautions (5.1)].
BACKGROUND: Non-syndromic cleft lip with or without cleft palate (NSCL/P) is a prevalent craniofacial birth defect on a global scale. A number of candidate genes have been identified as having an impact on NSCL/P. However, the association between interferon regulatory factor 6 (IRF6) polymorphisms and NSCL/P has yielded inconsistent results, prompting the need for a meta-analysis to obtain more accurate estimates.
METHODS: We conducted a thorough screening of all relevant articles published up until November 15, 2023, in online bibliographic databases. The statistical analysis of the collected data was performed using the Comprehensive Meta-Analysis (Version 4.0) software.
RESULTS: A total of 79 case-control studies, comprising 14,003 cases and 19,905 controls, were included in our analysis. The combined data indicated that the IRF6 rs642961 and rs2235371 polymorphisms were associated with an increased risk of NSCL/P in the overall population. However, no significant association was found between the rs2013162 and rs2235375 polymorphisms and the risk of NSCL/P in the overall population. Furthermore, subgroup analyses revealed significant correlations between the IRF6 rs642961, rs2235371, and rs2235375 polymorphisms and the risk of NSCL/P based on ethnic background and country of origin. Nevertheless, the rs2013162 polymorphism plays a protective role in Caucasians and mixed populations.
CONCLUSIONS: Our collective data indicates a significant association between the rs642961 and rs2235371 polymorphisms and the risk of NSCL/P in the overall population. The rs2235375 polymorphism could influence the susceptibility to NSCL/P based on ethnic background. Meanwhile, the rs2013162 polymorphism provides protective effects in Caucasian, mixed populations, and the Brazilian population.
PURPOSE: A cosmetic composition containing surface modification powder is provided to prevent pore from being blocked and improve stability of cosmetic product. CONSTITUTION: A cosmetic composition contains surface modification powder. The surface modification powder is obtained by modifying powder surface with copolymer denoted by chemical formula 1. In chemical formula 1, R1 and R3 are H or CH3. R2 is alkyl group of 1-5 carbon atoms, X is CpF2p+1 or (CF2)qH. P is 5-15, q is 5-10, m is 1-50, and n is 1-10. The copolymer has diol group and fluorine group. The copolymer is prepared by using 3-mercaprtopropane 1,2-diol. The surface modification powder is contained in 0.01 weight%-20 weight% based on total composition.
People with SLE are at much higher risk for mortality due to atherosclerotic vascular disease (ASVD). Available data suggest that the usual mechanics of and risk factors for atherosclerosis are enhanced by factors such as corticosteroid use and SLE itself. This study will evaluate a medication and education program designed to prevent ASVD complications (primary prevention) or their recurrence (secondary prevention). The study will also measure the compliance and retention rate for the prevention program over 4 years.

Participants in this study will be randomized to receive either preventive heart disease medications or placebo. Participants in the medication arm will receive pravastatin alone or in combination with the following: aspirin, ramipril, or a combination of vitamins B6, B12, and folate. All participants in this study will receive basic education on how to optimize their heart health. Educational material will be sent to the patients as well as to support persons whom they have named. One group will receive tailored education based on a particular risk factor. Participants will have three study visits and follow-up telephone visits four times a year. Study visits will include a medical history and basic laboratory blood tests. Participants with documented high blood pressure will receive a home monitoring unit and be asked to monitor their blood pressure. Participants will be followed for 2 to 4 years.
FIELD: medicine. SUBSTANCE: invention relates to novel stress correcting adaptogens. Invention proposes to use plant chufa, or earth almond, Cyperus esculentus L. as a tuber powder. Tuber powder of plant Cyperus esculentus L. used in daily dose 600 mg/kg before eating for 3 doses is an effective stress correcting adaptogen that enhances work ability of animals and human and exhibiting the protective effect under unfavorable conditions of emotional and physical factors of environment. EFFECT: enhanced effectiveness of adaptogen. 1 cl, 4 tbl, 4 ex
Belonging to the technical field of medicine, the invention relates to an antitumor drug oxaliplatin composition. The composition comprises: oxaliplatin and arginine. The oxaliplatin is crystal, and the X-ray powder diffraction pattern obtained by Cu-Kalpha ray measurement is shown as Figure 1. The new crystal form of oxaliplatin provided by the invention is different from the crystal structure of the prior art. Experimental verification finds that the new crystal form compound has the advantages of high purity, good fluidity, good stability, low impurity content, difficult absorption of moisture, and safe and reliable clinical application. The powder-injection obtained by the new crystal form compound has good stability, is stable after compatibility with a solvent, and has very low insoluble particle content, thus being very suitable for clinical application.